Santa Cruz Ventures

RealSeq Biosciences specializes in advanced RNA fragmentomics technology focused on enhancing the detection of diseases to improve diagnosis and treatment. The company's innovative proprietary methods facilitate bias-free small RNA and miRNA next-generation sequencing (NGS) library construction, making their technology particularly valuable in biomarker discovery, liquid biopsy, and single-cell analysis. RealSeq's applications are primarily directed towards cancer and infectious diseases, enabling healthcare providers to enhance patient outcomes through its cutting-edge RNA-based services.